- Home
- RGC vs MDWD Comparison
RGC vs MDWD Comparison
Compare RGC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- MDWD
- Stock Information
- Founded
- RGC 2014
- MDWD 2000
- Country
- RGC Hong Kong
- MDWD Israel
- Employees
- RGC N/A
- MDWD N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- RGC Health Care
- MDWD Health Care
- Exchange
- RGC Nasdaq
- MDWD Nasdaq
- Market Cap
- RGC 105.3M
- MDWD 184.8M
- IPO Year
- RGC 2021
- MDWD 2014
- Fundamental
- Price
- RGC $4.86
- MDWD $19.02
- Analyst Decision
- RGC
- MDWD Strong Buy
- Analyst Count
- RGC 0
- MDWD 1
- Target Price
- RGC N/A
- MDWD $25.00
- AVG Volume (30 Days)
- RGC 8.8K
- MDWD 61.7K
- Earning Date
- RGC 10-25-2024
- MDWD 11-26-2024
- Dividend Yield
- RGC N/A
- MDWD N/A
- EPS Growth
- RGC N/A
- MDWD N/A
- EPS
- RGC N/A
- MDWD N/A
- Revenue
- RGC N/A
- MDWD $19,720,000.00
- Revenue This Year
- RGC N/A
- MDWD $10.37
- Revenue Next Year
- RGC N/A
- MDWD $26.36
- P/E Ratio
- RGC N/A
- MDWD N/A
- Revenue Growth
- RGC N/A
- MDWD N/A
- 52 Week Low
- RGC $3.03
- MDWD $11.04
- 52 Week High
- RGC $32.44
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- RGC 44.96
- MDWD 61.79
- Support Level
- RGC $4.75
- MDWD $15.80
- Resistance Level
- RGC $5.21
- MDWD $18.25
- Average True Range (ATR)
- RGC 0.30
- MDWD 0.88
- MACD
- RGC 0.04
- MDWD 0.07
- Stochastic Oscillator
- RGC 23.87
- MDWD 95.27
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.